Manage Account
Change Password
Sign Out
Rheumatoid arthritis
Adult: In severe, active and progressive cases, not previously treated with methotrexate; or in moderate to severe cases, when response to at least one disease modifying antirheumatic drug (DMARD) or tumour necrosis factor (TNF) inhibitor has been inadequate, or in those who are intolerant of these drugs: As monotherapy or in combination with methotrexate or other non-biological DMARDs: Initially, 4 mg/kg every 4 weeks via infusion over 1 hour. May increase dose to 8 mg/kg based on clinical response. Max: 800 mg per dose. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Dosing recommendations may vary among countries or individual products. Refer to specific product guidelines.
Intravenous
Cytokine release syndrome
Adult: In severe or life-threatening cases that are due to chimeric antigen receptor-T (CAR-T) cell therapy: As monotherapy or in combination with corticosteroids: Patient weighing <30 kg: 12 mg/kg; Patient weighing ≥30 kg: 8 mg/kg. Max: 800 mg per dose. Doses are given via infusion over 1 hour. If clinical improvement does not occur after the 1st dose, up to 3 additional doses may be given with at least an 8-hour interval between consecutive doses.
Child: ≥2 years Same as adult dose.
Child: ≥2 years Same as adult dose.
Intravenous
Coronavirus disease 2019 (COVID-19)
Adult: In hospitalised patients requiring respiratory support (e.g. supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation [ECMO]): In combination with corticosteroids: Patient weighing <30 kg: 12 mg/kg; patients weighing ≥30 kg: 8 mg/kg. Max: 800 mg per infusion. Doses are given as a single infusion over 1 hour. If clinical improvement does not occur, a 2nd dose may be given at least 8 hours after the 1st dose. Dosage recommendation is based on currently available data from clinical studies and may vary among local guidelines or countries.
Child: ≥2 years Same as adult dose.
Elderly: Same as adult dose.
Child: ≥2 years Same as adult dose.
Elderly: Same as adult dose.
Intravenous
Polyarticular juvenile idiopathic arthritis
Child: As monotherapy or in combination with methotrexate: ≥2 years weighing <30 kg: 10 mg/kg; weighing ≥30 kg: 8 mg/kg. Max: 800 mg per dose. Doses are given once every 4 weeks via infusion over 1 hour. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Intravenous
Systemic juvenile idiopathic arthritis
Child: As monotherapy or in combination with methotrexate: ≥2 years weighing <30 kg: 12 mg/kg; weighing ≥30 kg: 8 mg/kg. Max: 800 mg per infusion. Doses are given once every 2 weeks via infusion over 1 hour. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Subcutaneous
Rheumatoid arthritis
Adult: In severe, active and progressive cases, not previously treated with methotrexate; or in moderate to severe cases, when response to at least one DMARD or TNF inhibitor has been inadequate, or in those who are intolerant of these drugs: As monotherapy or in combination with methotrexate or other non-biological DMARDs: Patient weighing <100 kg: Initially, 162 mg once every 2 weeks, increased to 162 mg once every week based on clinical response; Patient weighing ≥100 kg: 162 mg once weekly. Transitioning from IV to SC therapy: Administer the 1st SC dose instead of the next scheduled IV dose. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Dosing recommendations may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Polyarticular juvenile idiopathic arthritis
Child: As monotherapy or in combination with methotrexate: ≥2 years weighing <30 kg: 162 mg once every 3 weeks; weighing ≥30 kg: 162 mg once every 2 weeks. Transitioning from IV to SC therapy: Administer the 1st SC dose instead of the next scheduled IV dose. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Subcutaneous
Systemic sclerosis associated interstitial lung disease
Adult: 162 mg once every week. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline).
Subcutaneous
Systemic juvenile idiopathic arthritis
Child: As monotherapy or in combination with methotrexate: ≥1 year weighing <30 kg: 162 mg once every 2 weeks; weighing ≥30 kg: 162 mg once every week. Transitioning from IV to SC therapy: Administer the 1st SC dose instead of the next scheduled IV dose. Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Dosing recommendations may vary among countries or individual products. Refer to specific product guidelines.
Subcutaneous
Giant cell arteritis
Adult: In combination with a tapering course of glucocorticoid or as monotherapy following discontinuation of glucocorticoid: 162 mg once weekly or every 2 weeks (based on clinical considerations). Dose reduction, dosing interruption or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Dosing recommendations may vary among countries or individual products. Refer to specific product guidelines.